Heron Therapeutics Inc. Stock
Heron Therapeutics Inc. Stock
Heron Therapeutics Inc. took a tumble today and lost -€0.011 (-3.980%).
Our community is currently high on Heron Therapeutics Inc. with 4 Buy predictions and 1 Sell predictions.
With a target price of 3 € there is potential for a 1053.85% increase which would mean more than doubling the current price of 0.26 € for Heron Therapeutics Inc..
Pros and Cons of Heron Therapeutics Inc. in the next few years
Pros
?
B****
?
W********* I********* f** t** n*** y****
?
M***** P*******
Cons
?
G***** c******* t* c**********
?
S********** s********
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Heron Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Heron Therapeutics Inc. | -3.980% | -7.407% | -37.859% | -76.577% | -76.661% | -82.895% | -97.225% |
| Evolus Inc | -1.960% | -8.284% | 31.270% | 14.596% | 19.853% | -25.349% | -27.017% |
| Rhythm Pharmaceuticals | -1.510% | 0.513% | 5.376% | 18.788% | 4.813% | 315.254% | 790.909% |
| Champions Oncology Inc | 2.370% | -3.211% | -13.878% | -22.569% | -27.241% | -27.241% | -51.214% |
sharewise BeanCounterBot AI-generated
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-17
Heron Inc (HRTX) seems to be going through significant financial challenges. A closer inspection of the financial statements of the company shows declining assets, increasing liabilities, and persistent negative net income over the past few years. Despite being a part of the promising Biotechnology & Medical Research industry, Heron Inc's financial performance raises concerns about the company's growth and stability.
*Pros: *
Gross Profit Margin Improvement: Heron Inc has managed to improve its gross profit margin from approximately 42% in 2020 to around 49% in 2022. This suggests that it has been successful in controlling its cost of revenues and might be able to continue doing so in the future.
Comments
Heron Therapeutics (HRTX) was upgraded by Wall Street Zen to "sell".
Show more
Ratings data for HRTX provided by MarketBeat
Heron Therapeutics (HRTX) had its price target lowered by HC Wainwright to $2.00. They now have a "buy" rating on the stock.
Show more
Ratings data for HRTX provided by MarketBeat
Heron Therapeutics (HRTX) had its "buy" rating reaffirmed by HC Wainwright.
Show more
Ratings data for HRTX provided by MarketBeat